ReviewMolecular cancer2023
Advancements in nanoparticle-based treatment approaches for skin cancer therapy.
Review in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 307 citations in OpenAlex.
- Targeted nanotherapeutic strategy for melanoma using silk-fibroin based artemisinin nanoparticles.RSC advances · 2026Article
- Comparative In Vitro Response of HaCaT and A375 Melanoma Cells to Zinc Oxide Nanoparticles Synthesized Using Puerarin.Journal of xenobiotics · 2026Article
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Nanoscale delivery systems for hepatocellular carcinoma: Functionalization, delivery strategies, and clinical challenges.Materials today. Bio · 2026Review
- Evaluating the mechanisms and therapeutic potential of ZnO nanoparticles as selective anticancer agents for lung malignancies.Discover nano · 2026Review
- Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.Nanoscale advances · 2026Review
- Mycoendophytic-Derived Green Resveratrol-Conjugated Silver Nanoparticles Inhibit the Proliferation of Human Epidermoid Carcinoma A-431 Cells.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Transdermal Delivery of Sonidegib via Iontophoresis from PEDOT:PSS/Gelatin Hydrogels for Basal Cell Carcinoma Skin Cancer.Pharmaceutics · 2026Article
- Transferosomes as Advanced Nanocarriers for Enhanced Drug Delivery in Skin Cancer Therapy: A Comprehensive Review.Applied biochemistry and biotechnology · 2026Review
- Class-balanced dermoscopic lesion segmentation using MoG-LISA and optimized Swin-UNet via the GM-FDE framework.iScience · 2026Article
- Wearable bioelectronics for skin cancer management.Biomaterials · 2026Review
- Quercetin and Its Nano-Based Formulations Against Skin Cancer: A Narrative Review.Health science reports · 2026Article
- Nanoencapsulated senotherapeutic compounds targeting connexin-43 for enhanced wound healing.iScience · 2026Article
- Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.RSC advances · 2026Review
- Nanoemulgels as Advanced Topical Drug Delivery Systems: Mechanistic Insights and Therapeutic Applications in Skin Disorders, Infections, Wound Healing, and Cancer.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Navigating the Challenges of Metallopharmaceutical Agents: Strategies and Predictive Modeling for Skin Cancer Therapy.Pharmaceutics · 2026Review
- Nanotechnology in Skin Cancer Therapy: Recent Progress in Targeted Delivery.The Kaohsiung journal of medical sciences · 2026Review
- Engineering spherical nucleic acids for precision cancer therapy: design strategies and medical applications.Theranostics · 2026Review
- Optimization, Preparation, and Cytotoxic Potential ofCurrent topics in medicinal chemistry · 2026Article
- Recent Advances in Novel Drug Delivery Systems for the Management of Cutaneous Squamous Cell Carcinoma.International journal of nanomedicine · 2026Review
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer has emerged as the fifth most commonly reported cancer in the world, causing a burden on global health and the economy. The enormously rising environmental changes, industrialization, and genetic modification have further exacerbated skin cancer statistics. Current treatment modalities such as surgery, radiotherapy, conventional chemotherapy, targeted therapy, and immunotherapy are facing several issues related to cost, toxicity, and bioavailability thereby leading to declined anti-skin cancer therapeutic efficacy and poor patient compliance. In the context of overcoming this limitation, several nanotechnological advancements have been witnessed so far. Among various nanomaterials, nanoparticles have endowed exorbitant advantages by acting as both therapeutic agents and drug carriers for the remarkable treatment of skin cancer. The small size and large surface area to volume ratio of nanoparticles escalate the skin tumor uptake through their leaky vasculature resulting in enhanced therapeutic efficacy. In this context, the present review provides up to date information about different types and pathology of skin cancer, followed by their current treatment modalities and associated drawbacks. Furthermore, it meticulously discusses the role of numerous inorganic, polymer, and lipid-based nanoparticles in skin cancer therapy with subsequent descriptions of their patents and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.